News

Company   ImmuPharma PLC
TIDM         IMM
Headline     Trademark Approval
Released    07:00 13-May-08
Number     2381U07

FOR IMMEDIATE RELEASE

London, 13 May 2008

Lupus drug candidate IPP-201101 obtains trademark LUPUZOR ^TM

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today that it received approval of its trademark name LUPUZOR ^TM for its lead drug candidate for Lupus IPP-201101, by the US Patent and Trademark Office.

Immupharma has selected the trademark LUPUZOR ^TM for use in association with its peptide therapy for treating immunological disorders, including systemic lupus erythematosus (SLE). An application for reserving the right to use the LUPUZOR ^TM trademark was filed, and has now been allowed by the United States Patent and Trademark Office (Serial No. 77239130).

Dimitri Dimitriou, ImmuPharma’s CEO commented: “We believe LUPUZOR ^TM is a milestone in preparing for the commercialisation of our lead drug candidate for Lupus. The LUPUZOR TM brand will potentially facilitate the rapid market uptake of the compound by enabling a strong awareness from patients, physicians and healthcare organisations.”

LUPUZOR ^TM is currently undergoing a large Phase IIb clinical trial in Lupus patients in Europe and Latin America, results of which are expected later this year. LUPUZOR ^TM has already shown efficacy and safety in a small Phase II study in late 2006. LUPUZOR ^TM may reach the market in around two and a half years’ time, providing substantial revenues for the company.

For further information please contact:

ImmuPharma PLC

Dimitri Dimitriou, Chief Executive Officer                         +44 20 7152 4080
Dr Robert Zimmer, President & Chief Scientific Officer      + 33 389 32 7650
Richard Warr, Chairman                                                +44 20 7152 4080

Buchanan Communications + 44 20 7466 5000

Lisa Baderoon
Rebecca Skye-Dietrich

Panmure Gordon & Co +44 151 243 0963

Andrew Burnett


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	News Company ImmuPharma PLC TIDM IMM Headline Trademark Approval Released 07:00 13-May-08 Number 2381U07 FOR IMMEDIATE RELEASE London, 13 May 2008 Lupus drug candidate IPP-201101 obtains trademark LUPUZOR ^TM ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today that it received approval of its trademark name LUPUZOR ^TM for its lead drug candidate for Lupus IPP-201101, by the US Patent and Trademark Office. Immupharma has selected the trademark LUPUZOR ^TM for use in association with its peptide therapy for treating immunological disorders, including systemic lupus erythematosus (SLE). An application for reserving the right to use the LUPUZOR ^TM trademark was filed, and has now been allowed by the United States Patent and Trademark Office (Serial No. 77239130). Dimitri Dimitriou, ImmuPharma’s CEO commented: “We believe LUPUZOR ^TM is a milestone in preparing for the commercialisation of our lead drug candidate for Lupus. The LUPUZOR TM brand will potentially facilitate the rapid market uptake of the compound by enabling a strong awareness from patients, physicians and healthcare organisations.” LUPUZOR ^TM is currently undergoing a large Phase IIb clinical trial in Lupus patients in Europe and Latin America, results of which are expected later this year. LUPUZOR ^TM has already shown efficacy and safety in a small Phase II study in late 2006. LUPUZOR ^TM may reach the market in around two and a half years’ time, providing substantial revenues for the company. For further information please contact: ImmuPharma PLC Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080 Dr Robert Zimmer, President & Chief Scientific Officer + 33 389 32 7650 Richard Warr, Chairman +44 20 7152 4080 Buchanan Communications + 44 20 7466 5000 Lisa Baderoon Rebecca Skye-Dietrich Panmure Gordon & Co +44 151 243 0963 Andrew Burnett ©2008 London Stock Exchange plc. All rights reserved